emphasize the need for clarity in indications, protocol optimization, and pinpointing the patient demographics most likely to benefit [60]
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
To generate sufficient quantities of ROS and RNS quickly, these cells require rapid flux through the PPP to produce sufficient amounts of NADPH to enable superoxide formation from oxygen by the action of NADPH oxidase (NOX), and nitric oxide (NO) formation from arginine by inducible nitric oxide synthase (iNOS) ( Figure 1A-2 )
Can injectable vitamins be combined with other treatments
